

Mackenzie US Mid Cap Opportunities Fund Series A

US Equity

Compound Annualized Returns[†] 03/31/2024

| | |
|-----------------------------|-------|
| 1 Month | 2.7% |
| 3 Months | 8.9% |
| Year-to-date | 8.9% |
| 1 Year | 17.0% |
| 2 Years | 3.7% |
| 3 Years | 3.5% |
| Since inception (May, 2020) | 9.2% |

Regional Allocation 02/29/2024

| | |
|-------------------------------|------|
| CASH & EQUIVALENTS | |
| Cash & Equivalents | 4.5% |

| | |
|----------------|-------|
| OVERALL | |
| United States | 95.5% |


Sector Allocation 02/29/2024

| | |
|------------------------|-------|
| Information Technology | 30.0% |
| Industrials | 26.4% |
| Health Care | 22.5% |
| Financials | 7.2% |
| Consumer Discretionary | 5.8% |
| Cash & Equivalents | 4.5% |
| Real Estate | 3.6% |


Portfolio Managers

Mackenzie Growth Team
Phil Taller, John Lumbers

Calendar Year Returns (%) 03/31/2024



Value of \$10,000 invested 03/31/2024



Major Holdings*** 02/29/2024

Major Holdings Represent 45.9% of the fund

| | |
|--|------|
| Charles River Laboratories International Inc | 5.5% |
| Vontier Corp | 5.1% |
| Akamai Technologies Inc | 5.0% |
| Westinghouse Air Brake Technologies Corp | 4.8% |
| Dexcom Inc | 4.6% |
| Cirrus Logic Inc | 4.6% |
| ExlService Holdings Inc | 4.4% |
| Broadridge Financial Solutions Inc | 4.1% |
| Bio-Techne Corp | 3.9% |
| Maximus Inc | 3.9% |

TOTAL NUMBER OF EQUITY HOLDINGS: 31

Fund Risk Measures (3 year) 03/28/2024

| | | | |
|------------------------|-------|--------------|------|
| Annual Std Dev | 14.94 | Beta | 0.91 |
| B'mark Annual Std Dev. | 15.34 | R-squared | 0.87 |
| | | Sharpe Ratio | 0.06 |
| Alpha | -4.65 | | |

Source: Mackenzie Investments

Key Fund Data

| | |
|------------------------|-------------------|
| Total Fund Assets: | \$1.8 billion |
| NAVPS (03/28/2024): | C\$13.67 |
| MER (as of Sep. 2023): | A: 2.55% F: 1.05% |
| Management Fee: | A: 2.00% F: 0.80% |

Benchmark** : **Russell Mid Cap Total Return Index**
CDN

Last Paid Distribution:

| SERIES | FREQUENCY | AMOUNT | DATE |
|--------|-----------|--------|------------|
| A | Annually | 0.1021 | 12/23/2022 |
| F | Annually | 0.1224 | 12/23/2022 |
| T8 | Monthly | 0.0928 | 3/22/2024 |
| PW | Annually | 0.1069 | 12/23/2022 |

Fund Codes:

| SERIES (C\$) | PREFIX | FE | BE * | LL2 * | LL3 * |
|--------------|--------|------|------|-------|-------|
| A | MFC | 8108 | 8109 | 8111 | 8110 |
| F | MFC | 8113 | — | — | — |
| T8 | MFC | 8130 | 8131 | 8133 | 8132 |
| PW | MFC | 8119 | — | — | — |

Additional fund series available at
mackenzieinvestments.com/fundcodes

Morningstar Equity Investment Style

| | VALUE | BLEND | GROWTH |
|------------|-------|-------|--------|
| LARGE CAP | | | |
| MEDIUM CAP | | | |
| SMALL CAP | | | |

Why Invest in this fund?

- Access mid cap stocks that can offer a unique risk-return 'sweet spot' between fast-growing small businesses and mature large companies.
- Leverage our team's investment edge to discern between ideas and real business opportunities.
- Seek alpha in an under-researched universe of US mid caps with a concentrated portfolio of high-quality, innovative, secular growth businesses.

Risk Tolerance

| | | |
|-----|--------|------|
| LOW | MEDIUM | HIGH |
|-----|--------|------|



* Effective June 1, 2022, the redemption charge purchase option, and the low-load purchase option are no longer available for purchase, including those made through systematic purchase plans such as pre-authorized contribution plans. Switching from securities of a Mackenzie Fund previously purchased under the redemption charge or low-load purchase options to securities of another Mackenzie Fund, under the same purchase option, will continue to be available until such redemption schedules expire.

** The Russell Midcap Index (Net Return) measures the performance of the 800 smallest companies in the Russell 1000 Index.

*** The major holdings of the Fund may, but do not necessarily, represent the largest holdings of the Fund. Rather, the major holdings are selected for their overall significance in evaluating the investment portfolio.

† Commissions, trailing commissions, management fees, and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns as of March 28, 2024 including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution, or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Standard deviation provides a measure of the variability of returns that have occurred relative to the average return. The higher the standard deviation, the greater is the range of returns that has been experienced. Standard deviation is commonly used as a measure of risk.